Post-IPO Equity - Global Blood Therapeutics
Investment Firm
Overview
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Announced Date
Feb 21, 2017
Closed on Date
Feb 27, 2017
Funding Type
Post Ipo Equity
Highlights
Location
United States, North America
Social
Investor Lead
N/A
Participant Investors
1
No investment info available on this profile
Round Details and Background
Global Blood Therapeutics raised $143800000 on 2017-02-21 in Post-IPO Equity
GBT is a clinical-stage biopharmaceutical company developing a therapy for sickle cell disease.
Company Funding History
7
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Aug 01, 2017 |  Post-IPO Equity - Global Blood Therapeutics | - | 125.0M | |
| Jun 26, 2019 | Post-IPO Equity - Global Blood Therapeutics | - | 200.0M | |
| Jan 06, 2015 | Series B - Global Blood Therapeutics | 4 | - | 48.0M |
| Jun 14, 2012 | Series A - Global Blood Therapeutics | 1 | - | 40.7M |
Recent Activity
There is no recent news or activity for this profile.